Besins Manufacturing Belgium

Active

Public limited companyfounded 194976 yrs activeWashingtonstraat 80, 1050 Elsene, BelgiumKBO/BCE: BE 0401.981.955

Summary

Besins Manufacturing Belgium has been active since 1949 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €5.69M and a net result of €1.98M. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 25% of 85 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.5% (low).

Watch Print / PDF

Checked score

Score 2024

62 / 100

Healthy

The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.

Axes · tick = 2023

Profitability72▲+1

Solvency49▲+10

Growth73▲+10

Track record100

Bankruptcy probability, 12 months

0.5% Low

0%0.5%1.5%4%10%≥ 25%

Credit up to €350k at 30 days acceptable

Liquidity short (current ratio 0.89 against 0.8 in 2023; short-term debt: 74.4% and cash: 11.7% of total assets), and 76.2% of the assets are financed with debt.

How do we compute the score and the probability?

Credit check for your own amount and term

Signals

Nine signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Long track record

A company with a long track record statistically fails less often than a young one.

KBO · incorporation date

Age against the risk zone

Higher-failure-rate region

In this region companies fail more often than in the rest of the country.

KBO · registered office

Multiple establishment units

Several establishment units mean more fixed costs, and such companies fail more often than a company with one establishment.

KBO · establishment units

Lower-risk legal form

Companies with this legal form statistically fail less often than a BV.

KBO · legal form

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2024

Solvency, return and age of the figures

Solvency

23.8%

Return on assets

8.3%

Age of the figures

21 mo

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 21

Relative position

BE, all sectors

reference

Sector 21

higher

← fewer bankruptcies more bankruptcies →

Weak solvency vs sector

Solvency (equity / total assets) is in the sector's weakest quartile: better than 25% of 85 sector peers (2024).

NBB · sector comparison

Position among 85 sector peers

Solvency

better than 25%

← weakest strongest →

Growing equity

Reported equity is higher than in 2022 and did not fall compared with 2023. These amounts do not establish the cause of the change.

NBB · annual accounts 2024

Equity per financial year

192021222324

2019 to 2024 · latest year €5.69M

Filed after the deadline

The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 01-10-2025, 62 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.

NBB · 10 filings

Deviation from the deadline

2025

not confirmed

2024

62 d late

2023

64 d late

2022

13 d early

2021

9 d early

2020

40 d early

2019

22 d early

← before the deadline after the deadline →

Checked, nothing found (1)

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2024, full schema

Turnover

€39.08M▼ 3.4%

2023 · €40.44M

2019: €23.71M 2020: €23.16M 2021: €20.84M 2022: €33.48M 2023: €40.44M

2019 → 2024

EBIT margin

7.2%▲ 0.4pp

2023 · 6.8%

2019: -10.1% 2020: -5.4% 2021: -12.5% 2022: -2.8% 2023: 6.8%

2019 → 2024

Net result

€1.98M▲ 1.6%

2023 · €1.95M

2019: €-2.44M 2020: €-1.32M 2021: €-2.70M 2022: €-1.12M 2023: €1.95M

2019 → 2024

Working capital

€-1.88M▲ 55.7%

2023 · €-4.25M

2019: €-362k 2020: €-1.25M 2021: €-3.96M 2022: €-4.71M 2023: €-4.25M

2019 → 2024

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line20202021202220232024Trend

Turnover€23.16M-€20.84M▼ 10.0%€33.48M▲ 60.7%€40.44M▲ 20.8%€39.08M▼ 3.4%

Equity€4.27M-€1.58M▼ 63.1%€1.77M▲ 12.0%€3.72M▲ 110%€5.69M▲ 53.2%

Operating result€-1.26M-€-2.60M▼ 107%€-936k▲ 64.1%€2.74M€2.82M▲ 2.7%

Net result€-1.32M-€-2.70M▼ 104%€-1.12M▲ 58.6%€1.95M€1.98M▲ 1.6%

Result per fiscal year

Operating resultNet result

After the dip in 2021 the operating result has climbed three years in a row; 2024 is 3% above 2023 and is the highest result in the available series.

Balance-sheet composition

2024 in colour, 2023 as the grey bar beneath

Assets €23.95M

33.4%

66.6%

Fixed assets €8.01M ▼ 9.0%

Current assets €15.94M ▼ 6.8%

Equity and liabilities €23.95M

23.8%

75.4%

Equity €5.69M ▲ 53.2%

Provisions €191k ▲ 20.6%

Debt €18.07M ▼ 18.0%

Debt's share of the balance-sheet total falls from 85.1% to 75.4%. Equity is higher and debt is lower.

Key figures and ratios

2024 value · change against 2023

EBITDA

€4.09M▲

2023 · €3.80M

Cash flow

€3.25M▲

2023 · €3.01M

Current ratio

0.89▲

2023 · 0.80

Quick ratio

0.51▲

2023 · 0.40

Debt to equity

3.17▼

2023 · 5.93

ROE

34.7%▼

2023 · 52.4%

ROA

8.3%▲

2023 · 7.5%

Interest coverage

5.73▼

2023 · 7.03

Debt ≤ 1 year

€17.82M▼

2023 · €21.36M

Debt > 1 year

€247k▼

2023 · €583k

Income taxes

€123k▼

2023 · €251k

Staff costs

€8.25M▲

2023 · €8.06M

Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Filed annual accounts As filed with the NBB · 2024 against 2023 · 82 lines

Balance sheet Code20232024

Assets

Total assets20/58€25.91M€23.95M▼

Fixed assets21/28€8.80M€8.01M▼

Tangible fixed assets22/27€8.77M€7.98M▼

Land and buildings22€1.67M€1.52M▼

Plant, machinery and equipment23€4.73M€5.68M▲

Furniture and vehicles24€253k€348k▲

Assets under construction and advance payments27€2.12M€439k▼

Financial fixed assets28€31k€31k=

Other financial fixed assets284/8€31k€31k=

Amounts receivable and cash guarantees285/8€31k€31k=

Current assets29/58€17.11M€15.94M▼

Stocks and contracts in progress3€8.67M€6.92M▼

Stocks30/36€8.67M€6.92M▼

Raw materials and consumables30/31€5.09M€4.67M▼

Work in progress32€33k€14k▼

Finished goods33€3.54M€2.24M▼

Amounts receivable within one year40/41€4.52M€6.21M▲

Trade receivables40€4.03M€4.01M▼

Other amounts receivable41€489k€2.21M▲

Cash at bank and in hand54/58€3.89M€2.79M▼

Deferred charges and accrued income490/1€31k€13k▼

Equity and liabilities

Total equity and liabilities10/49€25.91M€23.95M▼

Equity10/15€3.72M€5.69M▲

Contributions10/11€11.72M€11.72M=

Capital10€11.72M€11.72M=

Issued capital100€11.72M€11.72M=

Reserves13€281k€281k=

Non-distributable reserves130/1€136k€136k=

Legal reserve130€135k€135k=

Reserves not available under the articles1311€878€878=

Tax-exempt reserves132€61k€61k=

Distributable reserves133€84k€84k=

Profit (loss) carried forward14€-8.29M€-6.31M▲

Provisions and deferred taxes16€158k€191k▲

Provisions for liabilities and charges160/5€158k€191k▲

Pensions and similar obligations160€158k€191k▲

Amounts payable17/49€22.04M€18.07M▼

Amounts payable after more than one year17€583k€247k▼

Financial debts170/4€583k€247k▼

Other loans174€583k€247k▼

Amounts payable within one year42/48€21.36M€17.82M▼

Current portion of amounts payable after more than one year42€48k€210k▲

Trade debts44€7.30M€3.31M▼

Suppliers440/4€7.30M€3.31M▼

Taxes, remuneration and social security45€1.10M€1.06M▼

Taxes450/3€253k€130k▼

Remuneration and social security454/9€843k€927k▲

Other amounts payable47/48€12.91M€13.25M▲

Accrued charges and deferred income492/3€100k€0▼

Income statement Code20232024

Operating income70/76A€41.09M€38.50M▼

Turnover70€40.44M€39.08M▼

Change in stocks of work in progress, finished goods and contracts in progress71€-620k€-1.66M▼

Other operating income74€635k€953k▲

Non-recurring operating income76A€631k€132k▼

Operating charges60/66A€38.34M€35.68M▼

Goods for resale, raw materials and consumables60€20.16M€18.49M▼

Purchases600/8€21.65M€17.71M▼

Change in stocks: decrease (increase)609€-1.49M€783k▲

Services and other goods61€9.68M€8.18M▼

Remuneration, social security and pensions62€8.06M€8.25M▲

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1.06M€1.27M▲

Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€-833k€-701k▲

Provisions for liabilities and charges: additions (uses and reversals)635/8€28k€33k▲

Other operating charges640/8€55k€153k▲

Non-recurring operating charges66A€132k€0▼

Operating profit (loss)9901€2.74M€2.82M▲

Financial income75/76B€0-

Recurring financial income75€0-

Other financial income752/9€0-

Financial charges65/66B€545k€716k▲

Recurring financial charges65€545k€716k▲

Debt charges650€541k€713k▲

Other financial charges652/9€4k€3k▼

Profit (loss) for the period before taxes9903€2.20M€2.10M▼

Income taxes67/77€251k€123k▼

Taxes670/3€253k€123k▼

Tax adjustments and reversals of tax provisions77€2k€0▼

Profit (loss) for the period9904€1.95M€1.98M▲

Profit (loss) for the period to be appropriated9905€1.95M€1.98M▲

Appropriation of the result

Profit (loss) to be appropriated9906€-8.29M€-6.31M▲

Profit (loss) brought forward from the previous period14P€-10.24M€-8.29M▲

Social balance

Average headcount (FTE)908798.4100.0▲

The notes to these accounts (67 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Timeline · acts, filings and financial milestones

All 46Financial 5Gazette 31Filings 10

2026

13-07

State Gazette act Resignation: Guevork MIKAELIAN (director)

Appointment: Geert NEUTTIENS (director) · Mandate compensation4 facts ▸

General meeting, 01-07-2026
Director resignation, Guevork MIKAELIAN (director)
Director appointment, Geert NEUTTIENS (director)
Mandate compensation, Geert NEUTTIENS

2025

20-10

State Gazette act Reappointment: Forvis Mazars Réviseurs d'Entreprises SRL (statutory auditor)

Permanent representative: Antoine Drugmand3 facts ▸

General meeting, 12-09-2025
Auditor reappointment, Forvis Mazars Réviseurs d'Entreprises SRL (statutory auditor)
Permanent representative, Antoine Drugmand

01-10

NBB filing Annual accounts filed

fiscal year 2024 · full schema · 62 days late

2024

31-12

Financial Highest result since 2019net €1.98M ▲1.6%

Operating result €2.82M, net result €1.98M, both a record.

31-12

Financial Equity above €5MEq €5.69M ▲53.2%

2 profitable years in a row build equity to €5.69M.

03-10

NBB filing Annual accounts filed

fiscal year 2023 · full schema · 64 days late

22-05

State Gazette act Appointment: Nicolas BESINS (director)

Mandate compensation5 facts ▸

General meeting, 23-04-2024
Director appointment, Nicolas BESINS (director)
Mandate compensation, Nicolas BESINS
Board meeting, 23-04-2024
Director appointment, Nicolas BESINS (managing director)

2023

31-12

Financial Back to profitnet €1.95M

Net result €1.95M after 4 loss-making years.

31-12

Financial Equity above €2MEq €3.72M ▲110%

Equity rises from €1.77M to €3.72M.

18-07

NBB filing Annual accounts filed

fiscal year 2022 · full schema

17-02

State Gazette act Resignation: EY réviseurs d’entreprise (statutory auditor)

Appointment: Mazars Réviseurs d'entreprises SRL (statutory auditor) · Permanent representative: Peter Lenoir · Director discharge6 facts ▸

General meeting, 21-12-2022
Director resignation, EY réviseurs d’entreprise (statutory auditor)
Director discharge, EY réviseurs d’entreprise
Power of attorney, Michel Vincent
Auditor appointment, Mazars Réviseurs d'entreprises SRL (statutory auditor)
Permanent representative, Peter Lenoir

2022

13-06

State Gazette act Registered office

Registered-office move2 facts ▸

Board meeting, 18-05-2022
Registered-office move, Rue Washington 80, 1050 Ixelles, Belgique

Show earlier events

10-05

State Gazette act Resignation: Financière Sébastien Aguettant (director)

Permanent representative: Sébastien Aguettant5 facts ▸

General meeting, 14-04-2022
Board meeting, 14-04-2022
Director resignation, Financière Sébastien Aguettant (director)
Director resignation, Financière Sébastien Aguettant (managing director)
Permanent representative, Sébastien Aguettant

28-04

State Gazette act Resignations & appointments

Name change · Statutes amendment4 facts ▸

General meeting, 21-04-2022
Name change, Besins Manufacturing Belgium
Statutes amendment
Statutes amendment

15-04

State Gazette act Capital & shares · Statutes amendment

Capital increase · Capital · Power of attorney6 facts ▸

Capital increase, €1.306.073
Capital, €11.723.851
Statutes amendment
Power of attorney, Stéphanie Ernaelsteen
Power of attorney, Daphné Bosnic
Power of attorney, Martin Pierreux

11-03

State Gazette act Resignation: Delpharm Industrie (director)

Appointments: Alexandre Besins, Daniel Delarbre and Financière Sébastien Aguettant · Permanent representative: Sébastien Aguettant · Director discharge12 facts ▸

General meeting, 17-01-2022
Director resignation, Delpharm Industrie (director)
Director discharge, Delpharm Industrie
Director appointment, Alexandre Besins (director)
Director appointment, Daniel Delarbre (director)
Mandate compensation, Alexandre Besins
Mandate compensation, Daniel Delarbre
Board meeting, 17-01-2022
Director appointment, Alexandre Besins (managing director)
Director appointment, Daniel Delarbre (managing director)
Director appointment, Financière Sébastien Aguettant (managing director)
Permanent representative, Sébastien Aguettant

11-03

State Gazette act Reappointment: EY Réviseurs d'entreprises SRL (statutory auditor)

Director discharge3 facts ▸

General meeting, 29-06-2020
Auditor reappointment, EY Réviseurs d'entreprises SRL
Director discharge, DELPHARM DROGENBOS

22-01

NBB filing Annual accounts filed

fiscal year 2021 · full schema

2021

30-06

Financial Weakest financial yearnet €-2.70M

Net result drops to €-2.70M, the lowest in the series; recovery starts the following year.

2020

22-12

NBB filing Annual accounts filed

fiscal year 2020 · full schema

22-04

State Gazette act Statutes amendment · Resignations & appointments

Name change · Capital5 facts ▸

General meeting, 02-03-2020
Name change, Delpharm Drogenbos
Statutes amendment
Capital, €10.417.778
Statutes amendment

09-01

NBB filing Annual accounts filed

fiscal year 2019 · full schema

2019

11-01

NBB filing Annual accounts filed

fiscal year 2018 · full schema

2018

15-05

State Gazette act Resignation: Carole RESMAN (représentant permanent de la société delpharm industrie, administrateur)

Appointment: Charles GAUDIN (représentant permanent de delpharm industrie) · Permanent representative: Charles GAUDIN4 facts ▸

General meeting, 02-01-2018
Director resignation, Carole RESMAN (représentant permanent de la société delpharm industrie, administrateur)
Director appointment, Charles GAUDIN (représentant permanent de delpharm industrie)
Permanent representative, Charles GAUDIN

28-02

State Gazette act Appointments: DELPHARM SAS, FINANCIERE SEBASTIEN AGUETTANT and DELPHARM INDUSTRIE

Permanent representatives: Sébastien Aguettant and Carole Resman · Resignations: DELPHARM SAS (managing director) and Carole Resman (managing director)10 facts ▸

Board meeting, 26-06-2012
Director appointment, DELPHARM SAS (managing director)
Permanent representative, Sébastien Aguettant
Board meeting, 23-10-2017
Director resignation, DELPHARM SAS (managing director)
Director resignation, Carole Resman (managing director)
Director appointment, FINANCIERE SEBASTIEN AGUETTANT (managing director)
Permanent representative, Sébastien Aguettant
Director appointment, DELPHARM INDUSTRIE (managing director)
Permanent representative, Carole Resman

2017

21-12

NBB filing Annual accounts filed

fiscal year 2017 · full schema

06-11

State Gazette act Resignations: Depharm SAS (director) and Delpharm Holding SAS (director)

Appointments: Financière Sébastien Aguettant (director) and Delpharm Industrie (director) · Permanent representatives: Sébastien Aguettant and Carole Resman · Reappointment: Ernst & Young Réviseurs d'Entreprises (statutory auditor)12 facts ▸

General meeting, 10-11-2016
Director resignation, Depharm SAS (director)
Director resignation, Delpharm Holding SAS (director)
Director discharge, Depharm SAS
Director discharge, Delpharm Holding SAS
Director appointment, Financière Sébastien Aguettant (director)
Permanent representative, Sébastien Aguettant
Director appointment, Delpharm Industrie (director)
Permanent representative, Carole Resman
Mandate compensation, Financière Sébastien Aguettant
Mandate compensation, Delpharm Industrie
Auditor reappointment, Ernst & Young Réviseurs d'Entreprises

2016

25-11

NBB filing Annual accounts filed

fiscal year 2016 · full schema

15-03

State Gazette act Reappointment: BST, Réviseurs d'entreprises (statutory auditor)

Appointment: Ernst & Young Réviseurs d'entreprises (commissaire réviseur) · Permanent representative: Vincent Etienne4 facts ▸

General meeting, 14-11-2013
Auditor reappointment, BST, Réviseurs d'entreprises
Auditor appointment, Ernst & Young Réviseurs d'entreprises (commissaire réviseur)
Permanent representative, Vincent Etienne

07-01

NBB filing Annual accounts filed

fiscal year 2015 · full schema

2013

30-12

State Gazette act Statutes amendment · Resignations & appointments

Name change3 facts ▸

General meeting, 04-12-2013
Name change, BESINS MANUFACTURING BELGIUM
Statutes amendment

08-10

State Gazette act Resignations & appointments

Name change · Statutes amendment3 facts ▸

General meeting, 17-09-2013
Name change, Delpharm Drogenbos
Statutes amendment

15-01

State Gazette act Capital & shares · Statutes amendment

Capital increase · Bank account · Capital6 facts ▸

General meeting, 13-12-2012
Capital increase, €3.107.378
Bank account, BNP PARIBAS FORTIS, 001-6859775-11
Capital, €10.417.778
Statutes amendment
Preemption waiver, partial waiver of legal pre-emptive subscription right, reserving part of the capital increase for BESINS HEALTHCARE

2012

03-08

State Gazette act Statutes amendment · Miscellaneous

2 facts ▸

General meeting, 29-06-2012
Statutes amendment

21-02

State Gazette act Resignations: Bruno Van den Broeck, Dominique Olivier and Antoine Besins

Registered-office move · Power of attorney6 facts ▸

Board meeting, 05-01-2012
Director resignation, Bruno Van den Broeck (managing director)
Director resignation, Dominique Olivier (managing director)
Director resignation, Antoine Besins (managing director)
Registered-office move, Rond Point Schuman 6, boîte 5 à 1040 Bruxelles
Power of attorney, Delpharm S.A.S.

07-02

State Gazette act Capital & shares · Statutes amendment

Capital increase · Bank account · Capital5 facts ▸

General meeting, 27-12-2011
Capital increase, €6.891.650
Bank account, BNP PARIBAS FORTIS, 001-6605794-73
Capital, €7.310.400
Statutes amendment

01-02

State Gazette act Resignations: Caroline Delvigne, Antoine Besins and 3 others

Appointments: Delpharm Holding (director) and Delpharm (director) · Permanent representatives: Carole Resman and Sébastien Aguettant · Director discharge19 facts ▸

General meeting, 05-01-2012
Director resignation, Caroline Delvigne (director)
Director resignation, Antoine Besins (director)
Director resignation, Dominique Olivier (director)
Director resignation, Leslie Grunfeld (director)
Director resignation, Bruno Van Den Broeck (director)
Director discharge, Caroline Delvigne
Director discharge, Antoine Besins
Director discharge, Dominique Olivier
Director discharge, Leslie Grunfeld
Director discharge, Bruno Van Den Broeck
Director appointment, Delpharm Holding (director)
+7 further facts in this act

09-01

State Gazette act Capital & shares

Share transfer · Power of attorney3 facts ▸

Share transfer, BESINS MANUFACTURING BELGIUM → BESINS HEALTHCARE
Power of attorney, Johan Lagae
Power of attorney, Els Bruls

06-01

State Gazette act Reappointment: BST Réviseurs d'Entreprises (statutory auditor)

2 facts ▸

General meeting, 26-07-2011
Auditor reappointment, BST Réviseurs d'Entreprises

2011

22-04

State Gazette act Appointment: Bruno VAN DEN BROECK (director)

4 facts ▸

General meeting, 22-03-2011
Director appointment, Bruno VAN DEN BROECK (director)
Board meeting, 22-03-2011
Director appointment, Bruno VAN DEN BROECK (managing director)

16-02

State Gazette act Resignations: Laurent GASTON (director) and Leslie GRUNFELD (daily management delegate)

Appointment: Dominique OLIVIER (director) · Mandate compensation8 facts ▸

General meeting, 21-10-2010
Director resignation, Laurent GASTON (director)
Director appointment, Dominique OLIVIER (director)
Mandate compensation, Dominique OLIVIER
Board meeting, 21-10-2010
Director resignation, Laurent GASTON (daily management delegate)
Director resignation, Leslie GRUNFELD (daily management delegate)
Director appointment, Dominique OLIVIER (managing director)

2010

05-11

State Gazette act Appointment: Leslie GRUNFELD (managing director)

Reappointment: Caroline Delvigne (director) · Mandate compensation5 facts ▸

Board meeting, 30-06-2010
Director appointment, Leslie GRUNFELD (managing director)
General meeting, 15-07-2010
Director reappointment, Caroline Delvigne (director)
Mandate compensation, Caroline Delvigne

02-03

State Gazette act Resignation: S.C.P.R.L. BST Réviseurs d'Entreprises (statutory auditor)

Reappointment: S.C.P.R.L. BST Réviseurs d'Entreprises (statutory auditor)3 facts ▸

General meeting, 15-10-2009
Director resignation, S.C.P.R.L. BST Réviseurs d'Entreprises (statutory auditor)
Auditor reappointment, S.C.P.R.L. BST Réviseurs d'Entreprises (statutory auditor)

2008

26-06

State Gazette act Statutes amendment

3 facts ▸

General meeting, 29-05-2008
Statutes amendment
Statutes amendment

2007

12-03

State Gazette act Resignation: Daniel De Grande (managing director)

Appointment: Florence de Meerschman (director) · Mandate compensation6 facts ▸

General meeting, 15-02-2007
Director resignation, Daniel De Grande (managing director)
Director appointment, Florence de Meerschman (director)
Mandate compensation, Florence de Meerschman
Board meeting, 15-02-2007
Director appointment, Florence de Meerschman (daily management delegate)

2005

01-08

State Gazette act Capital & shares · Statutes amendment · Resignations & appointments

Power of attorney6 facts ▸

General meeting, 08-07-2005
Statutes amendment
Statutes amendment
Statutes amendment
Statutes amendment
Power of attorney, BESINS INTERNATIONAL BELGIQUE

Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

31 of 32 acts read

About the unread acts

Of the 32 Belgian State Gazette acts we know for this company, 31 have been read. The other one has not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors

7 directors, last change in 2026

Geert NEUTTIENS

Director · since 01-07-2026

Current

Nicolas BESINS

Director · since 30-04-2024

Current

Alexandre Besins

Director · since 17-01-2022

Current

Daniel Delarbre

Director · since 17-01-2022

Current

Delpharm

Director · since 01-01-2012 · Legal entity · perm. rep.: Sébastien Aguettant

Not recently confirmed

Delpharm Holding

Director · since 01-01-2012 · Legal entity · perm. rep.: Carole Resman

Not recently confirmed

1 other director

Florence de Meerschman

Director · since 16-02-2007

Not recently confirmed

01-07-2026 Geert NEUTTIENS: Appointed as Director

01-07-2026 Guevork MIKAELIAN: Resigned as Director

30-04-2024 Nicolas BESINS: Appointed as Director

30-04-2024 Nicolas BESINS: Appointed as Managing director

12-04-2022 Financière Sébastien Aguettant: Resigned as Director

Full history in the Timeline (44 changes) →

Not every act has been read: a resignation may be missing here

1 of this company's 32 Belgian State Gazette acts has not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.

Location & real-estate footprint

Registered office, Elsene · 2 establishment units since 1950

seat establishment All 2 establishment units on the map

Ground area

3,997 m²

Building footprint

2,740 m²

Volume, LiDAR

16,747 m³

2 parcels, Brussels, Flanders · tallest building 13.5 m, ±4 floors. Linked by address, not a title deed.

7 companies at this address See who is registered here

2 establishment units

Groot-Bijgaardenstraat 128, 1620 Drogenbos

Manufacture of basic metals

since 19502.005.272.387

Besins Manufacturing Belgium

Washingtonstraat 80, 1050 ElseneManufacture of basic pharmaceutical products and pharmaceutical preparations

since 20072.164.973.385

2 parcels

Flanders 1 (50%) Brussels 1 (50%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
22001A0065/00A002	Flanders	3,723 m²	1 · 2,640 m²	10.1 m · 2 fl.
21447B0261/00T003	Brussels	274 m²	1 · 100 m²	13.5 m · 4 fl.

Linked by address, not proof of ownership

Methodology

via registered seat: 1 · via establishment units: 1

2 of 2 parcels with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Statutory auditor

1 auditor

FORVIS MAZARS REVISEURS D'ENTREPRISES SRLCurrent

Statutory auditor · represented by Antoine Drugmand

12-09-2025 → present

Show 3 earlier auditors

BST Réviseurs d'Entreprises Auditor succeeded by EY Réviseurs d'Entreprises SRL in 2013	15-10-2009 → 14-11-2013
EY Réviseurs d'Entreprises SRL Auditor succeeded by Mazars Réviseurs d'entreprises SRL in 2022	14-11-2013 → 21-12-2022
Mazars Réviseurs d'entreprises SRL Statutory auditor · represented by Peter Lenoir succeeded by FORVIS MAZARS REVISEURS D'ENTREPRISES SRL in 2025	21-12-2022 → 12-09-2025

Articles of association

Purpose

La société a pour objet de faire pour son compte ou pour compte d'autrui toutes opérations se rattachant directement ou indirectement à l'exploitation d'un laboratoire d'analyse…

Full purpose

La société a pour objet de faire pour son compte ou pour compte d'autrui toutes opérations se rattachant directement ou indirectement à l'exploitation d'un laboratoire d'analyse clinique, dans son sens le plus large, d'analyse de produits divers y compris les denrées alimentaires, et à la fabrication, au commerce, à l'importation et à l'exportation, à la transformation des produits chimiques produits divers et médicaments, à l'exploitation et à la reprise de licences de marques relatives à ces produits et médicaments.

according to the deed of 22-04-2020

Structure & network

Connections & network

1 connected company

Linked via shared directors

BNPP AM Pension Fund OFP

Shared director

→

Capital and shareholders

Shareholders according to the acts

After the capital increase act of 15-01-2013 ↗

BESINS HEALTHCARE (BE 0473.343.667) 31,212 shares
DELPHARM 93,083 shares

After the capital increase act of 07-02-2012 ↗

BESINS HEALTHCARE (BE 0473.343.667)

The Belgian State Gazette names shareholders only when an act mentions them; the share register itself is not published.

Capital over the years

15-04-2022 Capital increase of 1,306,073 EUR · to 11,723,851 EUR · 52,243 new shares
22-04-2020 Capital stated in the act · 10,417,778 EUR · 416,711 shares
15-01-2013 Capital increase of 3,107,378 EUR · to 10,417,778 EUR · 124,295 new shares
07-02-2012 Capital increase of 6,891,650 EUR · to 7,310,400 EUR · 275,666 new shares

Public money · subsidies and aid

Flemish government

2022 to 2025 · 3 entries · 4,771 EUR awarded · 4,771 EUR paid

Year	Entries	awarded	paid
2025	1	511 EUR	511 EUR
2023	1	3,578 EUR	3,578 EUR
2022	1	682 EUR	682 EUR

Schemes

Vlaams opleidingsverlof (VOV)

3 entries · 4,771 EUR · 4,771 EUR paid · Departement Werk en Sociale Economie

Similar companies · same sector, comparable size

N.V. Farmaceutische Laboratoria Trenker

Of 148 companies in sector 21201 we hold annual accounts for 116. 62 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Company data · Crossroads Bank

Identification

Legal formPublic limited company

Founded27-12-1949

Fiscal year end31-12

Activities, NACEBEL 2025

21201Manufacture of basic pharmaceutical products and pharmaceutical preparations

Sources

Crossroads Bank for EnterprisesBelgian Official Gazette · 31 actsNational Bank · 50 filingsAddress and cadastre registers

Scores and ratios are computed by Checked and are not a credit decision.